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T205 epitopes. These findings indicate that tau can be a 
lrrK2 substrate and that this interaction can enhance sali-
ent features of human disease.
Introduction
Mutations in leucine-rich repeat kinase 2 (LRRK2) are the 
most frequent cause of autosomal dominant and sporadic 
cases of Parkinson’s disease (PD) [12, 51, 60, 78]. The 
functions of lrrK2 are still largely unknown (reviewed 
in [6]), but aberrations in its kinase activity are thought to 
lead to pathogenesis [3, 9, 21, 31, 33, 67, 74]. Affected car-
riers of LRRK2 mutations are generally clinically indistin-
guishable from individuals with idiopathic PD and primar-
ily present with lewy body pathology [3, 19, 26, 61], but 
neuropathology is pleomorphic and often includes hyper-
phosphorylated tau protein inclusions [10, 17, 18, 43, 55, 
58, 61, 71, 75].
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Tau is a soluble protein that binds tubulin to promote 
microtubule (MT) assembly and support neuronal function 
(reviewed in [47]). While normal tau function is regulated 
by phosphorylation, certain phospho-epitopes are consid-
ered pathogenic [22] in tauopathies—neurodegenerative 
diseases that are characterized by the aggregation of hyper-
phosphorylated tau (reviewed in [68]). Tauopathies include 
Alzheimer’s disease (AD), progressive supranuclear palsy 
(PSP), Pick’s disease (PiD), and frontotemporal dementia 
and parkinsonism linked to chromosome-17 with muta-
tions in the tau gene (FTDP-17t), but tau inclusions are 
often observed in PD brains as well (reviewed in [32]). 
Furthermore, tau is also present in lewy bodies in familial 
and sporadic PD [14, 30]. Although FTDP-17t can result 
from mutations in the gene encoding tau [28, 54, 69], the 
cause of most tauopathies remains unknown. given this, 
identifying tau kinases and determining their involvement 
in tau pathogenesis are vital to therapeutic targeting of 
tauopathies.
The appearance of hyperphosphorylated, aggregated tau 
in the brain of some individuals with LRRK2 mutations 
(reviewed in [56]) has led to the suggestion that lrrK2 
may be a novel kinase for tau. Several studies, which dem-
onstrated altered tau phosphorylation in transgenic mice 
expressing mutant lrrK2, support this hypothesis [40, 
41, 46]. In addition, recent in vitro and cell culture stud-
ies suggest that lrrK2 may phosphorylate tau [35, 71]. 
If lrrK2 is a novel tau kinase, it is possible that it may 
phosphorylate novel tau epitopes; however, published stud-
ies have focused on a subset of the phospho-epitopes that 
are frequently associated with human tauopathies. Further-
more, an interaction between lrrK2 and tau has not been 
directly demonstrated in vivo and it is unclear if such an 
interaction could influence tau pathologies.
In the current report, we demonstrate that lrrK2 
directly phosphorylates tau in vitro and use mass spec-
trometry (MS) to identify specific tau epitopes that are 
targets of lrrK2 in vitro. We demonstrate that lrrK2 
preferentially phosphorylates tau at T149 and to a lesser 
extent T153—epitopes that have been largely unexplored 
by the tau field. We show these epitopes to be hyperphos-
phorylated in a range of human tauopathies and in indi-
viduals with the g2109S lrrK2 mutation using our novel 
antibodies. Finally, we demonstrate that human wild-
type lrrK2 expression in a mouse model of tauopathy 
enhances tau aggregation and tau hyperphosphorylation—
critical features of human tauopathy.
Materials and methods
recombinant forms of gST-lrrK2 (970–2,527) were 
purchased from Invitrogen. Full-length g2019S lrrK2 
was cloned into the mammalian expression vector 
pDeST27, expressed in HeK 293T cells and purified 
as previously described [8]. The human full-length tau 
cDNA cloned into the bacterial expression vector prK172 
was kindly provided by Dr. Michel goedert. recombi-
nant full-length 0N3r tau and fragments thereof were 
expressed in E. coli Bl21 and purified as previously 
described [27]. Tau mutations (e342V, P301l, P301S, 
and r406W) were introduced through site directed 
mutagenesis and verified by DNA sequencing. The mam-
malian expression plasmid peF-DeST51 with the full-
length wild-type (WT) (with or without a stop codon) or 
g2019S (with or without a stop codon) lrrK2 cDNAs 
to generate plasmids expressing full-length untagged 
lrrK2 (peF-DeST51-lrrK2, referred to as lrrK2) 
or full-length lrrK2 with a C-terminal V5-tagged (peF-
DeST51-lrrK2-V5, referred to as lrrK2-V5) were 
previously described [72]. Synthetic tau peptides TAU-A 
(KKAKgADgKTKIATPrgAAPPgQK) and TAU-B 
(rePKKVAVVrTPPKSPSSAKSrl) corresponding to 
residues 82–105 and 163–185, respectively, in 0N3r 
tau, as well as threonine to alanine specific mutants were 
synthesized and purified on reverse phase HPlC by gen-
Script USA Inc. These peptide sequences correspond to 
residues 140–163 and 221–243, respectively in 2N4r tau. 
recombinant myelin basic protein (MBP) was purchased 
from Millipore.
Antibodies
Anti-lrrK2 rabbit polyclonal antibody (1182) was previ-
ously described [72]. MJFF-4 (c81-8) was obtained from 
the Michael J. Fox Foundation. Anti-pT149 and anti-
pT153 tau specific antibodies were made as a service by 
genScript USA Inc. Briefly, rabbits were immunized with 
the pT149 peptide (DgKpTKIATPrgAAC) or pT153 
peptide (DgKTKIApTPrgAAC), affinity purified with 
the same peptide, and negatively absorbed against the non-
phosphorylated peptide (DgKTKIATPrgAAC). We used 
polyclonal tau antibodies e1 (specific for amino acids 19–
33 of human tau) [11], pT205 (Abcam), pT212 (Anaspec), 
pS214 (Invitrogen) [70], 17025 anti-tau (provided by Dr. 
Virginia lee, University of Pennsylvania, Philadelphia, 
PA); and monoclonal tau antibodies CP13 (specific for 
pS202 in tau), PHF1 (specific for pS396/S404 in tau), and 
MC1 [pre-PHF conformational epitope (7–9 and 326–
330)] (provided by Dr. Peter Davies, The einstein Institute 
for Medical research, Manhasset, NY, USA), AT8 (spe-
cific for pS199/pS202/pT205 in tau), AT100 (specific for 
pT212/S214 in tau), and AT270 (specific for pT181 in tau) 
(Innogenetics, Fisher Scientific). Other monoclonal anti-
bodies used were anti-V5 (Invitrogen) and anti-gAPDH 
(Biodesign).
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lrrK2 kinase assays
Unless otherwise noted, kinase assays were set up in a total 
volume of 25 μl with 25 nM recombinant gST–lrrK2 
(970–2,527) in 50 mM Tris/HCl (pH 7.5), 0.1 mM egTA, 
10 mM MgCl2 and 0.2 mM [γ-32P] ATP (4 Ci/mmol) in the 
presence of 10 μM of tau or MBP substrate, unless other-
wise noted. After incubation for 60 min at 30 °C, reactions 
were terminated by applying to individual 2.5 cm-diameter 
disks of P-81 phosphocellulose filter paper (Schleicher & 
Schuell, Keene, NH) that were immediately immersed 
in 75 mM phosphoric acid. After extensive washing with 
75 mM phosphoric acid, P-81 filters were rinsed with 
acetone and allowed to air dry. Filters were immersed in 
Cytoscint liquid scintillation cocktail (Fisher Scientific) 
and 32P radioactivity on each filter was measured by liquid 
scintillation using an lS6500 counter (Beckman Coulter). 
Km and Vmax parameters were calculated using graph-Pad 
Prism v5.02 (graphPad Software).
For phosphorylation analysis of recombinant tau pro-
teins with lrrK2, reactions were stopped with the addi-
tion of SDS-sample buffer and heating to 100 °C for 5 min. 
Samples were resolved onto SDS-polyacrylamide gels, 
and incorporation of phosphate was determined by auto-
radiography and/or immunoblotting with phospho-specific 
antibodies.
Mass spectrometry
As described above, 10 μM of 0N3r tau was sub-
jected to overnight in vitro phosphorylation by either 
g2019S lrrK2 or the kinase dead (KD) lrrK2 mutant 
D1994K. Samples were resolved onto SDS-polyacryla-
mide gels, and then excised and washed in 50 % ace-
tonitrile and water [5]. To maximize sequence coverage, 
three equivalently loaded and excised gel bands of 0N3r 
tau were separately digested with trypsin, chymotrypsin 
or gluC. Mass spectrometry (MS) analysis of modified 
0N3r tau was performed as a service by the Harvard 
Mass Spectrometry and Proteomics resource labora-
tory (Cambridge, MA, USA). Peptide sequence analysis 
of each digestion mixture was performed by microcap-
illary reversed-phase high-performance liquid chroma-
tography coupled with nanoelectrospray tandem mass 
spectrometry (μlC–MS/MS) on an lTQ-Orbitrap Velos 
mass spectrometer (ThermoFisher Scientific, San Jose, 
CA, USA). The Orbitrap repetitively surveyed an m/z 
range from 395 to 1,600, while data-dependent MS/MS 
spectra on the twenty most abundant ions in each survey 
scan were acquired in the linear ion trap. MS/MS spec-
tra were acquired with relative collision energy of 30 %, 
2.5-Da isolation width, and recurring ions dynamically 
excluded for 60 s. Preliminary sequencing of peptides 
was facilitated with the SeQUeST algorithm [15] with 
a 30 ppm mass tolerance against the human subset of 
the Uniprot Knowledgebase supplemented with a data-
base of common laboratory contaminants, concatenated 
to a reverse decoy database. Using a custom version of 
Proteomics Browser Suite (PBS v.2.7, ThermoFisher Sci-
entific, San Jose, CA, USA) peptide-spectrum matches 
(PSMs) were accepted with mass error <2.5 ppm and 
score thresholds to attain an estimated false discovery rate 
of ~1 %. Data-sets for all digest results were combined 
in silico, culled of minor contaminant PSMs, and re-
searched with SeQUeST algorithm against the 0N3r tau 
sequence without taking into account enzyme specific-
ity and with differential modifications of phosphorylated 
tyrosine, serine, and threonine residues. The discovery of 
phosphopeptides and subsequent manual confirmation of 
their MS/MS spectra were facilitated using in-house ver-
sions of programs MuQuest, graphMod, and FuzzyIons 
(PBS, ThermoFisher Scientific).
enzyme-linked immuno sorbent assay (elISA) to assess 
antibody specificity
recombinant C-terminal fragment of human 3r tau [C′ 
Tau] corresponding to amino acids 244–441 minus amino 
acids 275–305 that would be present in 2N4r tau human 
tau was phosphorylated with recombinant glycogen syn-
thase kinase 3 beta (gSK-3β) (New england Biolabs Inc, 
Ipswich, MA, USA) (20 mM Tris, pH 7.5, 10 mM MgCl2, 
5 mM DTT, 200 μM ATP, 1 mg/ml tau and 20,000 units 
enzyme in 50 μl) for 1 h at 30 °C. Controls included simi-
lar reactions without the kinase. 100 ng of each synthetic 
peptide or 500 ng of tau recombinant protein diluted in 
100 μl of water was absorbed per well of 96-well eIA/rIA 
Corning plates (Corning, NY, USA). The plates were 
extensively washed with PBS and blocked with PBS/5 % 
fetal bovine serum (FBS). Primary antibodies as indicated 
were diluted in PBS/5 % FBS and incubated on the plates. 
After extensive washes with PBS, plates were incubated 
with either anti-mouse antibody conjugated to HrP or 
anti-rabbit antibody conjugated to HrP diluted in PBS/5 % 
FBS. Plates were again extensively washed with PBS and 
reactions were carried out with 3,3′,5,5′-tetramethylbenzi-
dine (TMS) reagents (KPl, gaithersburg, NY, USA). The 
reactions were terminated by adding 0.2 M HCl and opti-
cal density was measured at OD450 using a Multiskan Plus 
plate reader (ThermoFisher). experiments were performed 
in quadruplicate.
Cell culture
HeK 293T cells were cultured in Dulbecco’s modified 
medium with high glucose (4.5 g/l) supplemented with 
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10 % FBS, 100 U/ml penicillin, 100 U/ml streptomycin, 
and 2 mM l-glutamine. Cells were plated onto 6-well 
plates and transfected at approximately 30 % conflu-
ence using lipofectamine 2000 according to the manu-
facturer’s protocol. Cells were maintained for 48 h after 
transfection. Cells were harvested and lysed in 3 % 
SDS/50 mM Tris–HCl, pH 6.8 and heated to 100 °C for 
5 min. Protein concentration was determined using BCA 
protein assay reagent and BSA as the standard (Pierce, 
Fisher Scientific). experiments were performed in 
duplicate.
Mice
Mice were housed and treated in accordance with the NIH 
guide for the Care and Use of laboratory Animals. All ani-
mal procedures were approved and conducted in accord-
ance with the Mayo Clinic Institutional Animal Care and 
Use committee and the University of Florida Institutional 
Animal Care and Use committee. Mice were maintained 
in a pathogen-free facility on a 12 h light/dark cycle with 
water and food provided ad libitum.
The parental TauP301l responder line and parental 
tTA activator line were generated and maintained on an 
FVB and 129/S6 background, respectively, as previously 
described [65]. Bigenic rTg4510 mice have forebrain-
focused expression of P301l transgenic tau. The paren-
tal bacterial artificial chromosome (BAC)-lrrK2 mice, 
maintained on an FVB background, contain the entire 
human LRRK2 gene including regulatory sequences 
and lrrK2 expression is driven by the human LRRK2 
promoter, as previously described [46]. Mice from the 
TauP301l responder line were crossed with mice from the 
BAC-lrrK2 mouse line for one generation to obtain 
lrrK2.TauP301l responder mice on an FVB background. 
lrrK2.TauP301l responder mice were then crossed with 
mice from the tTA activator line to obtain the resultant F1 
lrrK2/TauP301l mice on a 50 % FVB, 50 % 129S back-
ground, the same as the original rTg4510 mouse model 
[65]. All mice in this study were harvested at 5.5 months 
of age when mature cortical tangles and hippocampal neu-
rodegeneration are detectable in TauP301l only animals. We 
harvested 10 mice per group, half male and half female, 
for the four genotypes of interest (non-transgenic, lrrK2, 
TauP301l, and lrrK2/TauP301l). One male lrrK2/
TauP301l mouse did not overexpress lrrK2 (as deter-
mined by western blotting) and was excluded from all 
studies. The sarkosyl-preparation (see protocol below) of 
one female TauP301l mouse had extremely high tau aggre-
gation via western blotting and was identified by grubb’s 
analysis to be an outlier. As this may have been a tissue 
preparation error, all western blot data from this mouse 
were excluded from the final results.
Tissue harvest and preparation
All mice were euthanized by cervical dislocation to 
maintain the brain biochemistry by avoiding anesthesia-
induced tau changes. Brains were quickly removed, cut 
down the midline, and one brain half was drop fixed in 
10 % formalin for 24 h for immunohistochemical analysis 
and the other brain half was immediately homogenized to 
preserve the lrrK2 protein. Brains were homogenized 
in 6 volumes of homogenate buffer [50 mM Tris–HCl, 
pH 8.0, 274 mM NaCl, 5 mM KCl, 1 % protease inhibi-
tor mixture (Sigma), 1 % phosphatase inhibitor cocktails 
I and II (Sigma), and 1 mM phenylmethylsulfonyl fluo-
ride (PMSF)]. For lrrK2 analysis, homogenates were 
centrifuged at 150,000×g for 15 min at 4 °C. The super-
natants were collected and protein concentration was 
determined using BCA protein assay reagent and BSA as 
the standard. For tau analysis, the brain homogenate was 
diluted to 10 volumes using Tris-buffered saline and sub-
jected to sarkosyl fractionation as previously described 
[65]. Specifically, 200 μl of 10× homogenate was cen-
trifuged at 150,000×g for 15 min at 4 °C and the super-
natant, which contains soluble tau species, was collected 
and protein concentration was determined as described 
above. Pellets were homogenized in 3 volumes (600 μl) 
of Buffer B [10 mM Tris–HCl (pH 7.4), 0.8 M NaCl, 
10 % Sucrose, 1 mM egTA and 1 mM PMSF] and centri-
fuged at 150,000×g for 15 min at 4 °C. The supernatants 
were collected and incubated with 1 % sarkosyl (Sigma) 
for 1 h at 37 °C, followed by centrifugation at 150,000×g 
for 30 min at 4 °C to obtain a sarkosyl-soluble superna-
tant and sarkosyl-insoluble pellet. The sarkosyl-insoluble 
pellet, which contains the biochemical equivalent of neu-
rofibrillary tangles, was re-suspended in 20 μl Te buffer 
[10 mM Tris–HCl (pH 8.0), 1 mM eDTA].
Western blot analysis
For in vitro and cell culture experiments, equal amounts of 
protein samples were loaded and resolved by SDS-PAge, 
followed by electrophoretic transfer onto nitrocellulose 
membranes. Membranes were blocked in Tris-buffered 
saline (TBS) with 5 % non-fat milk powder, and incubated 
overnight with 1182 lrrK2-specific antibody [72], anti-
V5 antibody (Invitrogen), or anti-tau antibody (17025) in 
TBS/5 % non-fat milk powder. Membranes were also incu-
bated overnight with pT149 or pT153 tau specific antibod-
ies in TBS/5 % BSA. each incubation was followed by 
goat anti-mouse conjugated horseradish peroxidase (HrP) 
(Amersham Biosciences) or goat anti-rabbit HrP (Cell 
Signaling Technology), and immunoreactivity was detected 
using chemiluminescent reagent (NeN) followed by expo-
sure on X-ray film.
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For analysis of lrrK2 protein in mouse brain tissue, 
50 μg of protein was diluted in NuPAge lDS-sample 
buffer with NuPAge reducing agent (Invitrogen), boiled 
for 3 min at 95 °C, loaded onto 26-well 3–8 % Tris–Ace-
tate gels (Invitrogen), separated by SDS-PAge and trans-
ferred in NuPAge transfer buffer (Invitrogen) to PVDF 
membranes (Millipore, Fisher Scientific). Membranes 
were blocked for 1 h at room temperature in 5 % non-fat 
milk powder in TBS with 0.1 % Triton X-100 (TBS-T) 
and then incubated overnight in primary antibody diluted 
in 5 % non-fat milk powder in TBS-T at 4 °C. For tau pro-
tein analysis from mouse brain, 5 μg of the soluble frac-
tion or 3 μl of the sarkosyl-insoluble fraction was diluted 
in Novex Tris–glycine SDS-sample buffer (Invitrogen) 
with β-mercaptoethanol, heat denatured at 95 °C for 
5 min, loaded onto 26-well 10 % Tris–glycine gels (Invit-
rogen), separated by SDS-PAge and transferred in CAPS 
transfer buffer (Sigma) to PVDF membranes. Membranes 
were blocked in TBS-T with 5 % non-fat milk powder and 
incubated overnight with antibody in TBS-T/5 % non-fat 
milk powder, except for pT149 and pT153 tau antibod-
ies, which were in TBS-T/5 % BSA. All membranes were 
washed 3 times in TBS-T, incubated with either goat anti-
mouse HrP or goat anti-rabbit HrP secondary antibodies 
(Jackson Immunoresearch) for 1 h at room temperature 
and washed again 3 times in TBS-T. Membranes were 
developed using Western lightning Plus (Perkin elmer) 
and imaged using a FluorChem e System (ProteinSim-
ple). The relative levels of immunoreactivity were deter-
mined by densitometry using the software AlphaView SA 
(ProteinSimple).
Immunohistochemistry
Fixed mouse brains were paraffin embedded and cut into 
5 μm sagittal sections. Hematoxylin and eosin (H&e) 
staining was performed on at least two brain sections 
from each mouse to align all brains to approximately 
1.3 mm lateral to the midline using a mouse brain atlas 
[52]. Immunohistochemistry with the Dako Universal 
Autostainer with DAKO envision + HrP system (Dako) 
was performed with the following antibodies: pT149 tau, 
pT153 tau, AT8, AT270, CP13, and MC1. Stained slides 
were digitally scanned using a ScanScope XT scanner 
and were analyzed using ImageScope version 11.2.0.780 
software (Aperio). Positive pixel count algorithms were 
created to measure the staining density of the secondary 
antibody, specifically chromogen 3,3′ diaminobenzidine. 
The cortex of each animal was traced and analyzed using 
these algorithms and the burden was expressed as a per-
centage of immunostained pixels to total area. Sections 
that had tears or other artifacts were not included in the 
analysis.
Human tissue
Paraffin embedded sections were processed for immuno-
histochemistry as above for mice from 3r + 4r tauopa-
thy (5 AD—average age: 90 ± 6 years; 4 women; median 
Braak NFT Stage: VI; 2 with concurrent diffuse cortical 
lewy bodies), 4r tauopathy (4 PSP and 1 CBD—average 
age: 77 ± 7 years; 4 women; median Braak NFT Stage: 
III), 3r tauopathy (2 PiD—average age: 68 ± 6 years; 1 
woman; median Braak NFT Stage: III), and mutant lrrK2 
carriers (4 g2019S—average age: 76 ± 5 years; 2 women; 
Braak NFT Stage: 0–V). Sections were counterstained with 
hematoxylin.
Statistical analysis
grubb’s analysis was used to identify outliers in the west-
ern blot analysis of sarkosyl-insoluble tau. Data are pre-
sented as the mean ± standard error mean unless other-
wise noted. Analysis of two groups was performed with an 
unpaired, two-tailed Student’s t test while analysis of multi-
ple groups was analyzed by one-way ANOVA and post hoc 
Bonferroni multiple comparisons test (α = 0.05). Western 
blot and immunohistochemical data from male and female 
TauP301l and lrrK2/TauP301l mice were analyzed by two-
way ANOVA with genotype and sex as independent vari-
ables. All analyses were performed using graphPad Prism 
version 6.00 software (graphPad Software) and in all cases, 
P ≤ 0.05 was considered to be statistically significant.
Results
Wild-type and mutant lrrK2 phosphorylates multiple tau 
isoforms in vitro
To determine if lrrK2 directly phosphorylates tau, recom-
binant tau (2N4r) was incubated with multiple forms of 
recombinant gST-lrrK2 (970–2,527) and incorporation 
of γ-[32P] ATP was determined by autoradiography. Both 
wild-type (WT) and mutant (g2019S, I2020T and r1441C) 
lrrK2 phosphorylated recombinant tau in vitro (Fig. 1a). 
Although we analyzed three different lrrK2 mutants, 
each of which has been implicated in familial PD with neu-
rofibrillary tangle pathology, g2019S lrrK2 yielded the 
highest level of tau phosphorylation. Further, tau phospho-
rylation was largely ablated when using the lrrK2 kinase 
dead/impaired (KD) D1994K mutant (Fig. 1a), indicating 
that lrrK2 directly phosphorylated tau in vitro. We then 
examined the ability of mutant lrrK2 to phosphoryl-
ate different tau isoforms that contain alternatively spliced 
N-terminal (0, 1 or 2 N) and C-terminal MT-binding 
domains (3r or 4r). recombinant gST-g2019S lrrK2 
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(970–2,527) phosphorylated all forms of tau regardless 
of isoform or the presence of FTDP-17t-associated muta-
tions (e342V, P301l, P301S and r406W) (Fig. 1b). These 
findings were confirmed using full-length g2019S lrrK2 
(Supplemental Fig. 1).
Identification and characterization of tau residues 
phosphorylated by lrrK2 in vitro
To identify the tau residues that are phosphorylated by 
lrrK2 in vitro, we performed MS analyses of tau (0N3r) 
phosphorylated with gST-g2019S lrrK2 (970–2,527). 
Using the shortest tau isoform with the highest kinase 
active lrrK2, we had the greatest likelihood of complete 
coverage. We obtained >99 % sequence coverage from the 
0N3r isoform and identified multiple tau residues phos-
phorylated by g2019S lrrK2 (Fig. 2a), with T149, T153, 
T169, T205, T263 and T231 identified as the major phos-
phorylation sites by lrrK2 (Supplemental Table 1). These 
modifications were not present in identical MS analysis of 
0N3r tau incubated with KD lrrK2. To parse the sites 
that were preferentially phosphorylated by lrrK2, we 
incubated various forms of recombinant lrrK2 with syn-
thetic peptides that spanned short regions of tau containing 
1–3 potential tau phospho-epitopes (Supplemental Table 2) 
and quantified the resultant phosphorylation. g2019S-
lrrK2 showed the greatest phosphorylation of the Tau-A 
(KKAKgADgKTKIATPrgAAPPgQK) and Tau-B (reP-
KKVAVVrTPPKSPSSAKSrl) peptides, with the WT 
Tau-B peptide phosphorylated 83 ± 1.7 % (P < 0.001) less 
than the WT Tau-A peptide (Fig. 2b) as assessed by one-
way ANOVA and post hoc Bonferroni multiple compari-
sons test. The other peptides demonstrated minimal phos-
phorylation. These data were consistent with the MS data, 
which showed that pT149 and pT153 peptides were among 
the most abundant phosphorylated products resulting from 
lrrK2-mediated tau phosphorylation. Alanine substitu-
tion to block site-specific lrrK2 phosphorylation of the 
Tau-A peptide reduced phosphorylation by 93 ± 1.2 % 
(T149A; P < 0.0001) and 21 ± 1.2 % (T153A; P < 0.001) 
compared to WT Tau-A (Fig. 2b), indicating that tau T149 
and T153 were primary and secondary targets, respectively, 
of lrrK2-directed phosphorylation. We then assessed 
the kinetic features of WT and g2019S lrrK2 phospho-
rylation of Tau-A (see “Materials and methods”) where the 
concentration of Tau-A was varied as indicated while the 
concentration of ATP was constant at 200 μM. The Km of 
WT and g2019S lrrK2 for the Tau-A peptide was deter-
mined to be ~170 μM, which is similar to that of lrrK-
tide, the most robust and commonly used lrrK2 substrate 
in kinetic studies [1, 9, 31, 48]. Furthermore, like lrrK-
tide, the Vmax of tau phosphorylation by g2019S lrrK2 
was ~threefold greater than that of WT lrrK2 (Fig. 2c) 
[9].
Tau is phosphorylated at T149 and T153 in g2019S 
carriers and in a range of human tauopathies
To assess phosphorylation of tau T149 or T153, we created 
antibodies specific for each phospho-epitope (see “Materi-
als and methods”). elISA analysis of pT149 and pT153 
tau antibodies was used to establish the phospho-specific-
ity of each antibody. results showed that both antibodies 
are highly specific for tau peptides phosphorylated at their 
respective epitopes with minimal reactivity to non-phos-
phorylated tau peptide, non-phosphorylated C-terminal tau 
[C′ Tau] and C′ Tau phosphorylated by gSK-3β (Fig. 3a). 
In addition, pT149 antibody had minimal cross reactivity 
to tau peptide phosphorylated at T153 and the pT153 anti-
body had low cross reactivity to tau peptide phosphoryl-
ated at T149, but none when compared to the other control 
peptides. Both pT149 and pT153 antibodies recognized 
Fig. 1  Wild-type and mutant lrrK2 phosphorylates tau in vitro. a 
Wild-type (WT) and mutant lrrK2 proteins directly phosphoryl-
ate 2N4r tau in vitro. recombinant human tau (2N4r) is phospho-
rylated by recombinant WT, g2019S, I2020T, and r1441C human 
gST-lrrK2 (970–2,527), but not the kinase dead (KD) D1994K 
mutant as shown in duplicate by autoradiography (P32). Kinase activ-
ity of each lrrK2 construct was validated by lrrK2 auto-phos-
phorylation. b g2019S lrrK2 directly phosphorylates multiple tau 
isoforms with and without FTDP-17t mutations. recombinant gST-
g2019S lrrK2 (970–2,527) phosphorylates tau, regardless of tau 
isoform or mutation as shown by autoradiography (P32). In both a and 
b, Coomassie Blue (CB) shows equal loading of tau. Tau mutation 
abbreviations: EV e342V, PL P301l, PS P301S, RW r406W
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tau that had been incubated with gST-g2019S lrrK2 
(970–2,527), but not with gST-KD lrrK2 (970–2,527) 
(Fig. 3b). Further, HeK 293T cells were co-transfected 
with expression plasmids for 2N4r tau and pcDNA3.1, 
untagged full-length WT or g2019S lrrK2, or V5-tagged 
full-length WT or g2019S lrrK2. Immunoblot analy-
sis of cell lysates with total tau and pT149 tau antibodies 
confirmed that both tagged and untagged full-length WT 
and g2019S lrrK2 increased phosphorylation of tau at 
T149 in vivo by 8.4 ± 0.8-fold more (WT; P < 0.0001) 
and 7.5 ± 0.4-fold more (g2019S; P < 0.0001) than vec-
tor transfected control cells when normalized to total tau 
(Fig. 3c).
To test the pathological relevance of pT149 and pT153, 
we performed immunohistochemistry on brain tissue from 
different human tauopathies using our pT149 and pT153 
tau antibodies. Both antibodies recognized neurofibril-
lary pathology in AD (Fig. 3d, left panels), including 
neurofibrillary tangles, neuropil threads and dystrophic 
neurites in senile plaques. Further, both antibodies stained 
neurofibrillary tangles and tufted astrocytes (Fig. 3d, 
middle-left panels) in PSP, as well as Pick bodies in PiD 
(Fig. 3d, middle-right panels). Moreover, the pT149 and 
pT153 antibodies stained pathological tau in patients with 
the g2019S lrrK2 mutation (Fig. 3d, right panels). In 
addition to the tangle pathology previously reported for 
Fig. 2  lrrK2 phosphorylates multiple tau epitopes in vitro. a High-
lighted amino acids indicate residues of 0N3r tau phosphorylated 
by gST-g2019S lrrK2 (970–2,527), but not by kinase dead gST-
lrrK2 (970–2,527) as identified as putative sites by mass spectrom-
etry. We obtained coverage of ~99 % of the 0N3r construct as indi-
cated by capital letters. Major phosphorylation sites are highlighted in 
black. The entire amino acid sequence for the longest human tau iso-
form, 2N4r, is denoted and the tau domains, encoded by the alterna-
tively spliced exons 2, 3, and 10 that were not included in the 0N3r 
tau construct are boxed. b We compared gST-g2019S lrrK2 (970–
2,527) phosphorylation using synthetic peptides (Tau-A and Tau-B) 
as indicated by blue underlines in a. The degree of g2019S lrrK2-
directed phosphorylation of WT Tau-A (T149, T153) and Tau-B 
(T231) peptides was compared to Tau-A and Tau-B with individual 
alanine mutants (T149A, T153A, T231A), which blocked phospho-
rylation at each residue, to determine the relative substrate potential 
of each epitope. c Kinetics of gST-WT and -g2019S lrrK2 (970–
2,527) phosphorylation of Tau-A peptide. The concentration of Tau-A 
substrate was varied as indicated while the concentration of ATP was 
constant at 200 μM
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g2019S mutant carriers, our antibodies identified tau sur-
rounding lewy bodies in the brainstem (Fig. 3e). These 
results indicate that in addition to g2019S-lrrK2 car-
riers, tau hyperphosphorylation at T149 and T153 occurs 
in a range of human tauopathies, including so-called 
4r-tauopathies, 3r-tauopathies and 3r + 4r tauopathies, 
and that phosphorylation of these epitopes is linked to 
pathology, since no staining was detected in unaffected 
brains or unaffected brain regions in tauopathies (data not 
shown).
lrrK2 does not alter levels or phosphorylation of soluble 
tau in lrrK2/TauP301l mice
To determine, if lrrK2 could modify the development 
of tauopathy in vivo, we crossed human WT lrrK2 
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BAC mice that do not have an overt phenotype or patho-
logical abnormalities (including evidence of tau pathol-
ogy) [46], with rTg4510 mice that express human mutant 
(P301l) 0N4r tau [65] to generate mice that expressed 
both transgenes (lrrK2/TauP301l) (see breeding scheme 
in Supplemental Fig. 2). lrrK2 BAC mice showed the 
highest expression of transgenic lrrK2 in the hippocam-
pus as well as high expression in the cortex [46]. These 
regions overlap well with the forebrain-focused transgenic 
tau expression that is conditionally driven by a CAMKIIα-
tTA transgene in the rTg4510 mice [65], reducing the like-
lihood that an interaction between the proteins would be 
missed due to disparate expression profiles. The forebrain 
of 5.5-month-old rTg4510 mice, hereafter termed TauP301l, 
has been shown previously to have insoluble hyperphos-
phorylated tau, neurofibrillary tangles, and neuronal loss 
[59, 65]. We, therefore, examined lrrK2/TauP301l mice at 
5.5 months of age for alterations in this well-characterized 
pathology.
Initially, we confirmed that all lrrK2/TauP301l experi-
mental mice expressed the lrrK2 (Fig. 4a, b) and tau 
(Fig. 4c, d) transgenes. Soluble tau fractions typically con-
tain normal tau species that run at ~55 kDa which can be 
used to determine equal levels of expression across mice. 
Human lrrK2 expression in lrrK2/TauP301l mice did 
not affect human tau levels in the normal (soluble) fraction 
(Fig. 4c, d) when compared to TauP301l mice alone, ensur-
ing that any effects on tauopathy in the lrrK2/TauP301l 
mice would not be due to expression artifact. With a panel 
of phospho-specific tau antibodies, we then analyzed solu-
ble tau via western blotting for phosphorylation at sites that 
we confirmed to be directly phosphorylated by lrrK2 in 
vitro (T149 and T153) and/or identified by our initial MS 
results (T181, T212 and T205). We also included epitopes 
that are associated with human disease and were not identi-
fied by our MS analysis (S202, S214, and S396/S404). We 
did not detect any changes in the phosphorylation of the 
~55 kDa soluble tau in lrrK2/TauP301l mice when com-
pared to the TauP301l mice with any antibody utilized (Sup-
plemental Fig. 3). We and others have previously reported 
that species of higher molecular weight tau can be observed 
in the soluble fraction, potentially representing some spe-
cies of aggregated tau [39, 63, 64]. Interestingly, our pT153 
antibody recognized a ~64 kDa band in the soluble fraction 
of both TauP301l and lrrK2/TauP301l mice (Supplemental 
Fig. 3a). Comparison of this band between both cohorts 
(P = 0.17) failed, however, to reach our 0.05 threshold for 
significance.
Accumulation and phosphorylation of insoluble tau is 
increased in lrrK2/TauP301l mice
An important feature of human tauopathy and a subset of 
mutant lrrK2 carriers is the aggregation of tau. In tauopa-
thies, tau aggregation is associated with the shift of tau into 
the biochemically abnormal, sarkosyl-insoluble fraction. 
We, therefore, examined the sarkosyl-insoluble fractions of 
brains from lrrK2/TauP301l mice by western blot analysis 
to determine if lrrK2 enhances tau aggregation compared 
to TauP301l mice. Using the phospho-independent, human 
tau antibody, e1, we found that insoluble, aggregated tau 
levels were ~3.5 times higher in lrrK2/TauP301l com-
pared to TauP301l mice (Fig. 5a, b). Insoluble tau from both 
lrrK2/TauP301l and TauP301l mice migrated primarily as a 
~64 kDa band—a species that we have previously shown to 
correlate with the presence of NFTs in tau transgenic mice 
[39]. Using a two-way ANOVA (genotype × sex), we then 
determined that the levels of sarkosyl-insoluble human tau 
in TauP301l and lrrK2/TauP301l mice were affected by 
both genotype [F(1, 14) = 34, P < 0.0001] and sex [F(1, 
14) = 34, P < 0.0001], and that there was also a significant 
interaction between both factors [F(1, 14) = 14, P < 0.01]. 
To help interpret these findings, we analyzed females and 
males separately and found that female lrrK2/TauP301l 
mice had approximately 3.6 times more insoluble tau com-
pared to female TauP301l mice (P < 0.001) (Supplemen-
tal Fig. 4a), and that male lrrK2/TauP301l mice had 2.8 
Fig. 3  Novel pT149 and pT153 tau antibodies recognize human tau 
pathology. a elISA of phosphorylated and non-phosphorylated tau 
peptides with antibodies to pT149, pT153 and the PHF1 antibody, 
as a well-characterized control. The pT149 antibody reacted strongly 
with tau peptides phosphorylated at T149 while the pT153 antibody 
had the greatest interaction with tau phosphorylated at T153. Neither 
pT149 nor pT153 tau antibodies reacted with non-phosphorylated tau 
nor with the C-terminal half of 3r tau (C′ Tau) phosphorylated by 
gSK-3β. The pT153 antibody had low cross reactivity with tau phos-
phorylated at T149 as compared to non-phosphorylated C′ Tau, but 
not the other control peptides. ****P < 0.0001 [two-way ANOVA 
(antibody × peptide) with post hoc Bonferroni multiple compari-
sons test] (b) 0N3r tau was subjected to in vitro phosphorylation by 
either gST-g2019S (gS) or kinase dead (KD) lrrK2 (970–2,527) 
and analyzed via western blotting with 17025 (total tau), pT149 and 
pT153 antibodies. pT149 and pT153 antibodies recognize tau phos-
phorylated in vitro by g2019S lrrK2, but not tau incubated with 
the KD lrrK2. c HeK 293T cells were co-transfected with expres-
sion plasmids for 2N4r tau and pcDNA3.1, WT lrrK2-V5, gS 
lrrK2-V5, WT lrrK2 or gS lrrK2 and cell lysates were ana-
lyzed via western blot with lrrK2 (1182), V5, 17025 (total tau) and 
pT149 tau antibodies. Our novel pT149 antibody specifically detects 
tau phosphorylated by full-length WT and gS lrrK2 in cell cul-
ture. d In human tauopathies, pT149 (top panels) and pT153 (bot-
tom panels) tau antibodies recognized neurofibrillary tangles (filled 
arrows) and neuritic tau pathology (asterisk) associated with plaques 
in Alzheimer’s disease (AD, left panels), neurofibrillary tangles (filled 
arrows) and tufted astrocytes (arrowhead) in progressive supranu-
clear palsy (PSP, middle-left panels), Pick bodies (open arrows) in 
Pick’s disease (PiD, middle-right panels), and recognized neurofibril-
lary tangles (filled arrow) in g2019S lrrK2 patients (g2019S, right 
panels). e The pT149 antibody stains tau pathology surrounding a 
lewy body in the midbrain. Scale bar, 100 μm for panel d. Panel (e) 
is 50 μm × 50 μm
◂
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times more insoluble tau compare to male TauP301l mice 
(P < 0.05) (Supplemental Fig. 4b).
We then analyzed the sarkosyl-insoluble fraction of 
TauP301l and lrrK2/TauP301l mouse brains using our 
panel of phospho-tau antibodies and found that lrrK2 
increased phosphorylation of insoluble tau at all epitopes 
that were examined (Supplemental Figs. 5 and 6). To deter-
mine if the elevated levels of phosphorylated tau were 
simply driven by the overall increase of aggregated tau in 
the insoluble fraction, we normalized the densitometry of 
each phospho-tau antibody by the densitometry of sarko-
syl-insoluble human tau for each mouse. When normalized 
for the amount of insoluble tau in the sarkosyl-insoluble 
fraction, analysis by two-way ANOVA (genotype × sex) 
revealed a main genotype effect with increased phospho-
rylation of T149, T205, and S199/S202/T205 (Fig. 5c, 
g, h; Table 1) and decreased phosphorylation of T181 in 
lrrK2/TauP301l mice compared to TauP301l mice (Fig. 5e; 
Table 1). Phosphorylation of T153 in lrrK2/TauP301l 
mice compared to TauP301l mice (P = 0.07) did not reach 
our significance threshold (Fig. 5d; Table 1) and phospho-
rylation of S202, T212, S214, T212/S214 and S396/S404 
was unchanged by co-expression of lrrK2 in TauP301l 
mice (S202: P = 0.62; T212: P = 0.32; S214: P = 0.90; 
T212/S214: P = 0.63; and S396/S404: P = 0.40) (Fig. 5f, 
i–l; Table 1). In addition, this analysis revealed a main sex 
effect for pT181 (AT270), S199/S202/T205 (AT8) and 
S396/S404 (PHF1), but not the other epitopes examined 
(see statistical summary in Table 1).
lrrK2/TauP301l mice have enhanced cortical tau 
pathology
We sought to validate our biochemical studies with neu-
ropathological analysis of tau burden using antibodies 
that detect specific phosphorylation or conformational tau 
epitopes. All antibodies identified prominent tau pathol-
ogy, including neurofibrillary tangles, in the brains of 
TauP301l and lrrK2/TauP301l mice, which was absent in 
the lrrK2 only transgenic and non-transgenic (nTg) mice 
(Fig. 6). Tau pathology was distributed throughout the cor-
tex and hippocampus of TauP301l and lrrK2/TauP301l 
mice; however, we focused our assessment on the cortex 
since neuronal loss within the hippocampus can confound 
accurate assessment of tau burden at this age. Using two-
way ANOVA analysis, we observed significant increases 
in phosphorylated tau pathology in lrrK2/TauP301l mice 
with pT149, pT153, CP13, and AT8 immunostaining when 
Fig. 4  Tau expression in TauP301l transgenic mice is unaffected 
by addition of transgenic lrrK2 expression in TauP301l mice. The 
steady state amounts of lrrK2, human tau and gAPDH (load-
ing control) were estimated by western blot analyses of the soluble 
fractions of whole brain lysates from TauP301l and lrrK2/TauP301l 
mice. a representative western blot of lrrK2 and gAPDH with a 
non-transgenic littermate shown as a negative control. b Densitomet-
ric quantification of lrrK2 levels normalized to gAPDH. c repre-
sentative western blot of soluble human tau and gAPDH. d Densi-
tometric quantification of human tau levels normalized to gAPDH. 
Each dot represents an individual mouse with the mean indicated by 
the black line, n = 9 per cohort. ****P < 0.0001 [two-way ANOVA 
(genotype × sex): main effect of genotype indicated]
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Fig. 5  lrrK2/TauP301l mice 
have elevated insoluble, hyper-
phosphorylated tau compared to 
TauP301l. Western blot analyses 
of the sarkosyl-insoluble frac-
tions of whole brain lysates 
from TauP301l only and lrrK2/
TauP301l mice. a representative 
immunoblot probed with an 
antibody (e1) that recognizes 
human tau, regardless of phos-
phorylation state, shows signifi-
cantly more aggregated (insolu-
ble) human tau in lrrK2/
TauP301l compared to TauP301l 
only mice as measured by (b) 
densitometry. Note the ~64 kDa 
species of tau (a) that we have 
previously shown to be a highly 
aggregated, hyperphosphoryl-
ated form of 0N4r tau [64]. c–l 
levels of insoluble tau phos-
phorylated at T149 (c), T153 
(d), T181 (AT270) (e), S202 
(CP13) (f), T205 (g), S199/
S202/T205 (AT8) (h), T212 (i), 
S214 (j), T212/S214 (AT100) 
(k), and S396/S404 (PHF1) (l), 
as measured by densitometry 
(Supplemental Fig. 6), were 
adjusted by levels of human tau 
in the insoluble fraction (a-b) 
to distinguish specific phospho-
epitopes that are enriched in the 
insoluble fraction. Phosphoryla-
tion of insoluble tau is increased 
at T149, T205 and S199/S202/
T205 and decreased at T181 
when normalized to the amount 
of tau in the sarkosyl-insoluble 
fraction. Each dot represents an 
individual mouse with the mean 
indicated by the black line, 
n = 9 per cohort. *P ≤ 0.05, 
**P < 0.01, ***P < 0.001, 
****P < 0.0001 [two-way 
ANOVA (genotype × sex): 
main effect of genotype indi-
cated]. Summary of two-way 
ANOVA found in Table 1
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compared to TauP301l mice (Figs. 6, 7; Table 1). Although 
the burden of tau pathology with these antibodies was also 
significantly influenced by sex, where females had greater 
burden than males, there was no interaction between the 
genotype and sex (Fig. 7; Table 1). In addition, we observed 
significant increases in conformationally-abnormal tau in 
lrrK2/TauP301l mice with MC1 immunostaining when 
compared to TauP301l mice (Figs. 6, 7; Table 1). Tau bur-
den as assessed with MC1 was also significantly influenced 
by sex, but there was no interaction between genotype 
and sex (Table 1). No significant difference in tau burden 
was observed with AT270, irrespective of genotype or sex 
(Figs. 6, 7; Table 1).
Discussion
In the current study, we combined in vitro, cell culture, 
and novel transgenic studies to demonstrate that tau is a 
substrate of lrrK2 and that this interaction promotes 
tauopathy. We found that recombinant WT and mutant 
lrrK2 directly phosphorylates tau in kinase assays. As 
shown previously for other lrrK2 substrates, g2019S 
lrrK2 yields the greatest levels of tau phosphoryla-
tion [9, 21, 31, 74]. Our subsequent in vitro studies used 
g2019S lrrK2 to obtain the highest levels of sub-
strate phosphorylation, thereby reducing the chance that 
lrrK2-directed phosphorylation of tau would be inad-
vertently missed. Using MS analysis, we uncovered the 
tau epitopes that were potentially targeted by lrrK2 
phosphorylation. To reduce false positives, MS analysis 
was performed in parallel with reactions utilizing KD 
lrrK2, and we further validated subsequent hits using 
lrrK2 kinase reactions coupled with site directed 
mutagenesis at identified sites of phosphorylation to 
block lrrK2 activity. Surprisingly, we identified tau 
T149 and T153 as a preferential target and a secondary 
target, respectively, of lrrK2-directed phosphoryla-
tion. Although much of our studies focused on mutant 
lrrK2, we sought to determine if tau could be a sub-
strate of lrrK2 in vivo by generating novel transgenic 
mice, which expressed human WT lrrK2 and mutant 
tau. WT lrrK2 mice alone do not develop tau abnor-
malities and the tau abnormalities observed in mutant 
lrrK2 mice are modest [40, 41, 46]. For our lrrK2/
TauP301l model, we combined a WT lrrK2 BAC 
line [46] with a TauP301l (rTg4510) model [65]. The 
Table 1  Summary of 
sarkosyl-insoluble and 
immunohistochemical analysis 
of tau measured from female 
and male TauP301l and lrrK2/
TauP301l mice
Top statistical results 
from a two-way ANOVA 
(genotype × sex) of the 
densitometry of phospho-
specific tau antibodies 
normalized to the amount of 
human tau in the insoluble 
fraction for each mouse. Bottom 
Statistical results from a two-
way ANOVA (genotype × sex) 
of cortical staining with 
phospho- and conformational-
specific tau antibodies
Stain genotype Sex Interaction
F(DFn, DFd) P value F(DFn, DFd) P value F(DFn, DFd) P value
Two-way ANOVA of insoluble pTau normalized to insoluble human tau
 pT149 F(1, 14) = 15 P < 0.005 F(1, 14) = 0.001 P = 0.97 F(1, 14) = 0.01 P = 0.92
 pT153 F(1, 14) = 3.8 P = 0.07 F(1, 14) = 1.0 P = 0.33 F(1, 14) = 0.16 P = 0.70
 AT270 F(1, 14) = 7.73 P ≤ 0.05 F(1, 14) = 33.44 P < 0.0001 F(1, 14) = 0.66 P = 0.43
 CP13 F(1, 14) = 0.25 P = 0.62 F(1, 14) = 1.59 P = 0.23 F(1, 14) = 4.47 P ≤ 0.05
 pT205 F(1, 14) = 5.4 P ≤ 0.05 F(1, 14) = 1.9 P = 0.19 F(1, 14) = 0.01 P = 0.92
 AT8 F(1, 14) = 24 P < 0.0005 F(1, 14) = 64 P < 0.0001 F(1, 14) = 8.5 P ≤ 0.05
 pT212 F(1, 14) = 1.05 P = 0.32 F(1, 14) = 0.03 P = 0.87 F(1, 14) = 0.12 P = 0.74
 pS214 F(1, 14) = 0.02 P = 0.90 F(1, 14) = 0.07 P = 0.79 F(1, 14) = 2.17 P = 0.16
 AT100 F(1, 14) = 0.25 P = 0.63 F(1, 14) = 1.49 P = 0.24 F(1, 14) = 4.89 P = 0.04
 PHF1 F(1, 14) = 0.76 P = 0.40 F(1, 14) = 11.63 P < 0.005 F(1, 14) = 4.14 P = 0.06
TauP301l = 4 females, 5 males; lrrK2/TauP301l =5 females, 4 males
Two-way ANOVA of Tau Cortical Burden
 pT149 F(1, 14) = 4.5 P ≤ 0.05 F(1, 14) = 13 P < 0.005 F(1, 14) = 0.14 P = 0.71
 pT153 F(1, 14) = 5.0 P ≤ 0.05 F(1, 14) = 14 P < 0.005 F(1, 14) = 0.53 P = 0.48
 AT270 F(1, 14) = 0.22 P = 0.65 F(1, 14) = 0.24 P = 0.63 F(1, 14) = 0.32 P = 0.58
 CP13 F(1, 14) = 4.6 P ≤ 0.05 F(1, 14) = 6.0 P ≤ 0.05 F(1, 14) = 0.17 P = 0.69
 AT8 F(1, 14) = 8.5 P ≤ 0.05 F(1, 14) = 16 P < 0.005 F(1, 14) = 2.1 P = 0.17
 MC1 F(1, 14) = 6.1 P ≤ 0.05 F(1, 14) = 8.8 P ≤ 0.05 F(1, 14) = 0.76 P = 0.40
TauP301l = 5 females, 4 males; lrrK2/TauP301l = 5 females, 4 males
Fig. 6  Cortical staining of phospho- and conformational-specific tau 
antibodies in female non-transgenic (nTg), lrrK2 only, TauP301l 
and lrrK2/TauP301l mice. a–f representative images showing stain-
ing in the primary sensory cortex of female nTg, lrrK2, TauP301l 
and lrrK2/TauP301l mice with pT149 tau (a), pT153 tau (b), AT270 
(pT181 tau) (c), CP13 (pS202) (d), AT8 (pS199/S202/T205 tau) (e), 
MC1 and (f) antibodies. Scale bar 200 μm. CC corpus callosum
◂
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rTg4510 model represents a well-characterized model, 
providing a “primed system” in which we could deter-
mine if human lrrK2 phosphorylates tau in vivo and 
if this could influence the development of tauopathy. 
We demonstrated that human WT lrrK2 expression 
in a mouse model of tauopathy enhances tau aggrega-
tion and tau hyperphosphorylation—critical features of 
human tauopathy.
Having identified T149 and T153 on tau as primary tar-
gets of direct g2019S lrrK2 phosphorylation in vitro, 
we then sought to determine the relevance of these sites to 
human tauopathy. One study has reported that T149 tau is 
phosphorylated by recombinant CK1δ and gSK-3β kinases 
[23]; however, phosphorylation of T149 has not been stud-
ied in vivo or associated with disease. Phosphorylation of 
T153 has been described in vitro and in cell culture [23, 29, 
66] and one study shows that phospho-T153 (pT153) anti-
body labels neurofibrillary tangles in AD brain [2]. It is still 
unknown to what extent phosphorylation of T153 is associ-
ated with other tauopathies. We created antibodies specific 
for tau phosphorylated at T149 and at T153, respectively 
(see “Materials and methods”). We then confirmed their 
specificity in vitro and in cell culture and demonstrated the 
presence of these phospho-epitopes in neuronal and glial 
lesions of 3r tauopathies (PiD), 4r tauopathies (PSP) and 
3r + 4r tauopathies (AD) and in g2019S-lrrK2 carri-
ers (PD). There was also immunoreactivity in a subset of 
lewy bodies, similar to the pattern we previously noted 
with other antibodies to phospho-tau [30]. T149 and T153 
are largely unexplored tau epitopes, but it is of interest that 
they flank a rare variant in tau, A152T, that may be a risk 
factor for tauopathies such as PSP [7, 34, 36]. lrrK2 is 
not known to play a role in tauopathies beyond its involve-
ment in PD, but it is possible that rare genetic variants in 
lrrK2, including those that confer risk to PD [16, 60, 62] 
or have yet to be uncovered, could play a role in tauopa-
thies. The pT149 and pT153 immunostaining in these 
diverse cases of human tauopathy suggests that further 
studies on the role of lrrK2 in these disorders could be 
informative.
Fig. 7  lrrK2/TauP301l have 
elevated levels of cortical tau 
pathology compared to TauP301l 
mice. a–f There are specific 
increases of tau phosphoryla-
tion at epitopes T149, T153, 
S202 (CP13), S199/S202/
T205 (AT8), as well as tau 
with an abnormal conforma-
tion (MC1) in lrrK2/TauP301l 
mice versus TauP301l mice. No 
difference in phosphorylation 
of T181 (AT270) was observed 
when lrrK2/TauP301l mice 
were compared to TauP301l 
mice. Each dot represents an 
individual mouse with the mean 
indicated by the black line, 
n = 9 per cohort. *P ≤ 0.05 
[two-way ANOVA (geno-
type × sex): main effect of 
genotype indicated]. Summary 
of two-way ANOVA found in 
Table 1
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No changes to tau levels or phosphorylation were 
observed in the soluble fraction of lrrK2/TauP301l mice 
compared to TauP301l mice. Initial analysis of the insoluble 
fraction revealed increased phosphorylation of all epitopes 
examined in lrrK2/TauP301l mice. This was not surpris-
ing, however, as there was approximately three times more 
tau in the insoluble fraction of lrrK2/TauP301l mice. To 
account for the significant difference of insoluble tau in 
TauP301l only and lrrK2/TauP301l mice, it was necessary 
to adjust the phospho-tau levels to the total amount of insol-
uble tau present to fully assess if there were specific phos-
phorylation changes associated with lrrK2 overexpres-
sion. We found that co-expression of lrrK2 in TauP301l 
mice selectively increased insoluble tau phosphorylation 
at sites identified in vitro as being directly phosphoryl-
ated by lrrK2, T149 and T153, as well as the T205 and 
S199/S202/T205 epitopes. Interestingly, our in vitro results 
were performed in the context of soluble tau; whereas, the 
elevated phosphorylation in the mice in the presence of 
lrrK2 was only in insoluble tau. These data suggest that 
lrrK2-associated phosphorylation may be able to trigger 
the shift of soluble tau into the insoluble fraction. Davies 
et al. [13] have isolated a substantial amount of lrrK2 
in the insoluble protein fraction using a Triton and SDS 
preparation and demonstrated that lrrK2 is not exclu-
sively soluble in WT rodents or in humans. This could sup-
port a potential interaction of lrrK2 and tau in lrrK2/
TauP301l mice as tau switches from its highly soluble (nor-
mal) state to the insoluble protein that is found in tauopa-
thy. Alternatively, filamentous tau may be a better substrate 
for lrrK2 compared to the soluble tau. Neuropathologi-
cal analysis revealed increased tau burden using antibodies 
for tau phosphorylated at T149, T153, S202, and pS199/
S202/T205, largely replicating what we observed in our 
biochemical analysis. By both biochemical and histologi-
cal analyses enhanced phosphorylation was detected by the 
AT8 antibody that recognizes a triple epitope (pS199/S202/
S205). It is possible that these findings are due to increased 
phosphorylation at S202 or T205 that was observed with 
antibodies that specifically detect those singular epitopes.
Our in vitro and in vivo findings support that T149 tau 
is the primary target of direct lrrK2 phosphorylation and 
suggests that T153 may be a secondary target. Our MS 
studies identified T205 as a potential lrrK2 phosphoryla-
tion site which was not validated in our subsequent in vitro 
work utilizing synthetic peptides for this region; therefore, 
the increased phosphorylation of insoluble tau at T205 and 
the combined S199/S202/T205 epitope, recognized by 
the AT8 antibody, may indicate an indirect mechanism by 
which lrrK2 increases phosphorylation of these specific 
tau epitopes in vivo. Alternatively, phosphorylation of T205 
may require unique modeling of secondary and tertiary 
structure, and therefore be a better substrate for lrrK2 in 
vivo than it is in vitro. In addition, microtubules or other 
co-factors may act as scaffold to bring tau and lrrK2 
together, allowing lrrK2 to phosphorylate tau at addi-
tional epitopes [35]. lrrK2 might also directly phospho-
rylate other tau kinases and enhance their ability to target 
tau [49, 76], including AKT, gSK-3β, and members of the 
MAPK family, which have been implicated downstream of 
lrrK2 activity [4, 20, 42, 44, 53, 57]. In addition, lrrK2 
phosphorylation of its main target epitopes (i.e., T149) may 
have the ability to enhance phosphorylation of additional 
epitopes by other tau kinases; such cooperation has been 
noted with other phospho-tau epitopes [45, 77]. Further 
experiments examining the interaction between lrrK2-
associated tau phosphorylation and tau phosphorylation by 
known tau kinases are required to test this.
For proteins that are highly phosphorylated, such as tau, 
it is common to find redundancy of phosphorylation of a 
given residue by multiple kinases. For example, S202 tau 
has been shown to be phosphorylated by at least 8 differ-
ent kinases, including CK1 (reviewed in [37]). CK1δ has 
also been shown to phosphorylate T149 tau in vitro [23] 
and interestingly, both CK1δ and lrrK2 have been shown 
to phosphorylate the disease-related α-synuclein protein 
at S129 [50, 57]. given this, it would not be surprising if 
both kinases could phosphorylate tau at the same epitope. 
In Drosophila, lrrK2 has been proposed to increase tau 
phosphorylation at T212 in a gSK-3β dependent man-
ner [42]. In our lrrK2/TauP301l mice, we did not detect 
increased phosphorylation of tau at T212 nor at S396/S404, 
a second epitope phosphorylated by gSK-3β [38], indicat-
ing that lrrK2 expression in TauP301l mice did not ubiq-
uitously increase phosphorylation of tau epitopes targeted 
by gSK-3β (reviewed in [24]). Surprisingly, we observed 
a significant decrease in phosphorylation of insoluble tau 
at T181 in the lrrK2/TauP301l compared to TauP301l mice. 
Kawakami et al. [35] previously reported that lrrK2 did 
not promote phosphorylation of tau S199/S202/T205 in 
vitro and instead increased phosphorylation of T181 in cell 
culture and in vitro, a modification of tau that required the 
interaction with microtubules. Ujiie et al. [71] reported that 
lrrK2 modestly enhanced T181 phosphorylation in cell 
culture. The discrepancy between our findings and these 
reports may arise from differences between constructs or 
reaction design. Furthermore, the lrrK2/TauP301l mice 
express mutant tau, which has reduced tubulin binding [25, 
27], potentially decreasing our ability to uncover tubulin-
dependent lrrK2 phosphorylation of tau.
The evolution of toxic tau is a complex event, with 
no consensus on the biochemical switch from soluble to 
insoluble tau or functional to dysfunctional species. Our 
neuropathological analysis of lrrK2/TauP301l mice com-
pared to TauP301l mice revealed elevated immunostaining 
with the MC1 antibody, which detects tau in an abnormal, 
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disease-relevant conformation [73], agreeing with our bio-
chemical findings of increased 64 kDa sarkosyl-insoluble 
tau. Although our in vitro results suggest that the increase 
in tauopathy in the lrrK2/TauP301l mice is likely derived 
from the kinase function of lrrK2, it is possible that in 
vivo lrrK2 also promotes the aggregation of tau into 
the insoluble fraction by indirect cellular mechanisms. 
Other functions such as its regulation of autophagy have 
been assigned to lrrK2, which may contribute to our in 
vivo observations. In addition, some findings suggest that 
lrrK2-mediated tau phosphorylation can inhibit micro-
tubule binding [35], which could also promote tau aggre-
gation. Further studies will be required to determine the 
relative contribution of these alternative mechanisms on tau 
aggregation.
In some cases, we detected an influence of sex as well as 
genotype on neuropathological and biochemical outcomes 
in our mouse studies when assessed by two-way ANOVA. 
Neither transgenic tau nor lrrK2 expression was influ-
enced by sex; therefore, these differences are not easily 
explained, but they are interesting and could be physio-
logically important. Curiously, the age-associated cumula-
tive incidence of lrrK2 g2019S PD in Tunisia is gender 
specific—the median age of onset of female carriers being 
5 years younger (in preparation, Matthew J. Farrer). In our 
lab, we have observed a non-significant trend that female 
rTg4510 mice have steeper exponential phase of tau pathol-
ogy than male rTg4510 mice between ~4 and 6 months of 
age (personal communication, Jada lewis). This inherent 
difference may be amplified by lrrK2 influence on tau 
pathology.
Our data, in aggregate, demonstrate that lrrK2 directly 
phosphorylates tau at T149 and T153 in vitro and the ability 
of lrrK2 to phosphorylate tau at these sites may underlie 
its ability to promote tauopathy in our novel mouse model. 
Our current in vivo studies are the first of their kind and 
provide compelling evidence that lrrK2 and tau inter-
act in a disease-relevant manner. Further, the presence of 
phosphorylation at tau T149 and T153 in a variety of tau 
pathologies suggests that lrrK2 genetic studies in human 
tauopathies may be warranted.
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